[1]Budzinski,Julian;Huber,MaxE.;Kostenis,Evi;Merten,Nicole;Schiedel,Matthias;Schmidt,MaximilianF.;Toy,Lara;Vogt,Hannah;Weikert,Dorothee;Wiefhoff,MartinF.J.[AngewandteChemie-InternationalEdition,2022,vol.61,#12][Angew.Chem.,2022]
[2]CurrentPatentAssignee:CHEMOCENTRYXINC-WO2004/46092,2004,A2Locationinpatent:Page63-64
[3]CurrentPatentAssignee:CHEMOCENTRYXINC-WO2013/16174,2013,A1Locationinpatent:Page/Pagecolumn13;14
[4]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2014/155437,2014,A1Locationinpatent:Paragraph0118;0123;0124
[5]Westphal,MatthiasV.;Wolfstädter,BerndT.;Plancher,Jean-Marc;Gatfield,John;Carreira,ErickM.[ChemMedChem,2015,vol.10,#3,p.461-469]
[6]CurrentPatentAssignee:CHEMOCENTRYXINC-WO2005/113513,2005,A2Locationinpatent:Page/Pagecolumn158-159;180-181
[1]CurrentPatentAssignee:CHEMOCENTRYXINC-WO2004/46092,2004,A2Locationinpatent:Page87
[1]CurrentPatentAssignee:CHEMOCENTRYXINC-WO2005/113513,2005,A2Locationinpatent:Page/Pagecolumn163
[1]CurrentPatentAssignee:CHEMOCENTRYXINC-WO2005/113513,2005,A2Locationinpatent:Page/Pagecolumn159-160
[1]CurrentPatentAssignee:CHEMOCENTRYXINC-WO2005/113513,2005,A2Locationinpatent:Page/Pagecolumn161
Title: A New Series of Orally Bioavailable Chemokine Receptor 9 (CCR9) Antagonists; Possible Agents for the Treatment of Inflammatory Bowel Disease.
Journal: Journal of medicinal chemistry 20160414
Title: Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
Journal: The Journal of pharmacology and experimental therapeutics 20101001
Title: Walters MJ, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 2010 Oct;335(1):61-9.
Title: Bekker P, et al. CCR9 Antagonists in the Treatment of Ulcerative Colitis. Mediators Inflamm. 2015;2015:628340.
Title: Zhang J, et al. Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease. Bioorg Med Chem Lett. 2015 Sep 1;25(17):3661-4.